相关实验视频
Updated: May 6, 2026

04:38
A Murine Tail Lymphedema Model
Published on: February 10, 2021
5.6K
在患有极度肥胖和大量淋巴的患者中,塞马格卢提德治疗:一个病例报告
Joanne Thanh-Tâm Nguyen1, Marie-Amélie Barbet-Massin2, Emilie Pupier2
1Service d'endocrinologie, diabétologie et maladies métaboliques, CRMR Pradort, CHU de Bordeaux, Bordeaux, France, joanne.thanh-tam.nguyen@usherbrooke.ca.
Obesity facts
|September 9, 2024
概括
在由多学科团队管理的患者中,塞马格卢提德有效治疗极度肥胖和大规模局部淋巴 (MLL). 这种方法改善了流动性并减少了MLL,突出了有前途的治疗途径.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 血管医学 血管医学
背景情况:
- 极度肥胖 (BMI ≥50 kg/m2) 带来了复杂的挑战.
- 大规模局部淋巴 (MLL) 是极度肥胖的一个严重并发症.
- 对于管理MLL的极度肥胖而存在有限的文献.
相关概念视频
Drug Dosing: Obese Patients
374
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
374
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
448
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
448

